Danish pharmaceutical company ALK-Abello (CPH: ALK-B) has announced increased sales, revenue and profits in its annual report for 2015.
Net profit for the year was 344 million Danish kroner ($52 million) compared with 181million kroner ($27.35 million) in 2014 and the board has proposed a 5 kroner per share dividend.
Total revenue, including partner income, rose to 2,569 million kroner from 2,433 million kroner the year before.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze